Do analysts prefer APHA or CRON?

Cronos Group has a consensus target price of C$4.75, suggesting a potential upside of 19.65%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts clearly believe Cronos Group is more favorable than Aphria. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aphria 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, APHA or CRON?

Cronos Group has lower revenue, but higher earnings than Aphria. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aphria C$611.06M 0.00 -C$637.39M -C$2.01 N/A Cronos Group C$159.54M 9.30 -C$32.78M N/A N/A

Which has preferable earnings and valuation, PBH or CRON?

Premium Brands has higher revenue and earnings than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Premium Brands C$7.88B 0.59 C$99.56M C$0.90 98.68 Cronos Group C$159.54M 9.30 -C$32.78M N/A N/A

Do analysts rate CRON or BHC?

Cronos Group currently has a consensus price target of C$4.75, indicating a potential upside of 19.65%. Given Cronos Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cronos Group is more favorable than Bausch Health Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Bausch Health Companies 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, CRON or BHC?

Cronos Group has higher earnings, but lower revenue than Bausch Health Companies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group C$159.54M 9.30 -C$32.78M N/A N/A Bausch Health Companies C$10.53B 0.22 -C$125.65M -C$3.24 N/A

Do analysts rate CRON or AUP?

Cronos Group currently has a consensus target price of C$4.75, suggesting a potential upside of 19.65%. Given Cronos Group's stronger consensus rating and higher probable upside, research analysts plainly believe Cronos Group is more favorable than Aurinia Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, CRON or AUP?

Cronos Group has higher revenue and earnings than Aurinia Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group C$159.54M 9.30 -C$32.78M N/A N/A Aurinia Pharmaceuticals C$57.59M 0.00 -C$190.03M -C$1.48 N/A

Which has better earnings & valuation, CRON or SLS?

Cronos Group has higher revenue and earnings than Solaris Resources. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group C$159.54M 9.30 -C$32.78M N/A N/A Solaris Resources N/A N/A -C$46.49M -C$0.19 N/A

Cronos Group (CRON) Competitors

C$3.97 +0.09 (+2.32%)

As of 07/24/2026 04:00 PM Eastern

Compare

CRON vs. APHA, PBH, BHC, AUP, and SLS

Should you buy Cronos Group stock or one of its competitors? MarketBeat compares Cronos Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cronos Group include Aphria (APHA), Premium Brands (PBH), Bausch Health Companies (BHC), Aurinia Pharmaceuticals (AUP), and Solaris Resources (SLS). These companies are all part of the "pharmaceutical products" industry.

How does Cronos Group compare to Aphria?

Aphria (TSE:APHA) and Cronos Group (TSE:CRON) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Cronos Group has a consensus target price of C$4.75, suggesting a potential upside of 19.65%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts clearly believe Cronos Group is more favorable than Aphria.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aphria	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

4.3% of Cronos Group shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cronos Group has lower revenue, but higher earnings than Aphria.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aphria	C$611.06M	0.00	-C$637.39M	-C$2.01	N/A
Cronos Group	C$159.54M	9.30	-C$32.78M	N/A	N/A

In the previous week, Aphria's average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Overall Sentiment
Aphria	Neutral
Cronos Group	Neutral

Aphria has a net margin of 0.00% compared to Cronos Group's net margin of -1.29%. Aphria's return on equity of 0.00% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aphria	N/A	N/A	N/A
Cronos Group	-1.29%	-0.19%	-3.73%

Summary

Cronos Group beats Aphria on 6 of the 11 factors compared between the two stocks.

How does Cronos Group compare to Premium Brands?

Premium Brands (TSE:PBH) and Cronos Group (TSE:CRON) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Premium Brands has higher revenue and earnings than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Premium Brands	C$7.88B	0.59	C$99.56M	C$0.90	98.68
Cronos Group	C$159.54M	9.30	-C$32.78M	N/A	N/A

32.5% of Premium Brands shares are held by institutional investors. Comparatively, 4.3% of Cronos Group shares are held by institutional investors. 2.0% of Premium Brands shares are held by company insiders. Comparatively, 46.4% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Premium Brands had 4 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for Premium Brands and 0 mentions for Cronos Group. Premium Brands' average media sentiment score of 0.15 beat Cronos Group's score of 0.00 indicating that Premium Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Premium Brands	Neutral
Cronos Group	Neutral

Premium Brands currently has a consensus target price of C$118.62, suggesting a potential upside of 33.56%. Cronos Group has a consensus target price of C$4.75, suggesting a potential upside of 19.65%. Given Premium Brands' higher probable upside, research analysts plainly believe Premium Brands is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Premium Brands	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Premium Brands has a net margin of 0.52% compared to Cronos Group's net margin of -1.29%. Premium Brands' return on equity of 2.21% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Premium Brands	0.52%	2.21%	3.61%
Cronos Group	-1.29%	-0.19%	-3.73%

Premium Brands has a beta of 0.901611, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.126226, suggesting that its share price is 13% more volatile than the broader market.

Summary

Premium Brands beats Cronos Group on 11 of the 15 factors compared between the two stocks.

How does Cronos Group compare to Bausch Health Companies?

Cronos Group (TSE:CRON) and Bausch Health Companies (TSE:BHC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

4.3% of Cronos Group shares are owned by institutional investors. Comparatively, 10.7% of Bausch Health Companies shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by insiders. Comparatively, 11.3% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Bausch Health Companies had 6 more articles in the media than Cronos Group. MarketBeat recorded 6 mentions for Bausch Health Companies and 0 mentions for Cronos Group. Bausch Health Companies' average media sentiment score of 2.00 beat Cronos Group's score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the news media.

Company	Overall Sentiment
Cronos Group	Neutral
Bausch Health Companies	Very Positive

Cronos Group currently has a consensus price target of C$4.75, indicating a potential upside of 19.65%. Given Cronos Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cronos Group is more favorable than Bausch Health Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bausch Health Companies	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cronos Group has a net margin of -1.29% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.29%	-0.19%	-3.73%
Bausch Health Companies	-13.54%	120.43%	4.16%

Cronos Group has a beta of 1.126226, meaning that its share price is 13% more volatile than the broader market. Comparatively, Bausch Health Companies has a beta of 0.973491, meaning that its share price is 3% less volatile than the broader market.

Cronos Group has higher earnings, but lower revenue than Bausch Health Companies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$159.54M	9.30	-C$32.78M	N/A	N/A
Bausch Health Companies	C$10.53B	0.22	-C$125.65M	-C$3.24	N/A

Summary

Cronos Group beats Bausch Health Companies on 8 of the 15 factors compared between the two stocks.

How does Cronos Group compare to Aurinia Pharmaceuticals?

Cronos Group (TSE:CRON) and Aurinia Pharmaceuticals (TSE:AUP) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Cronos Group currently has a consensus target price of C$4.75, suggesting a potential upside of 19.65%. Given Cronos Group's stronger consensus rating and higher probable upside, research analysts plainly believe Cronos Group is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Aurinia Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cronos Group	Neutral
Aurinia Pharmaceuticals	Neutral

Aurinia Pharmaceuticals has a net margin of 0.00% compared to Cronos Group's net margin of -1.29%. Aurinia Pharmaceuticals' return on equity of 0.00% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.29%	-0.19%	-3.73%
Aurinia Pharmaceuticals	N/A	N/A	N/A

Cronos Group has higher revenue and earnings than Aurinia Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$159.54M	9.30	-C$32.78M	N/A	N/A
Aurinia Pharmaceuticals	C$57.59M	0.00	-C$190.03M	-C$1.48	N/A

Summary

Cronos Group beats Aurinia Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Cronos Group compare to Solaris Resources?

Cronos Group (TSE:CRON) and Solaris Resources (TSE:SLS) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Solaris Resources has a net margin of 0.00% compared to Cronos Group's net margin of -1.29%. Solaris Resources' return on equity of 60.97% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.29%	-0.19%	-3.73%
Solaris Resources	N/A	60.97%	-51.67%

Cronos Group has higher revenue and earnings than Solaris Resources.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$159.54M	9.30	-C$32.78M	N/A	N/A
Solaris Resources	N/A	N/A	-C$46.49M	-C$0.19	N/A

4.3% of Cronos Group shares are owned by institutional investors. Comparatively, 16.5% of Solaris Resources shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Comparatively, 40.6% of Solaris Resources shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cronos Group has a beta of 1.126226, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Solaris Resources has a beta of 1.777576, suggesting that its stock price is 78% more volatile than the broader market.

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Solaris Resources'average media sentiment score.

Company	Overall Sentiment
Cronos Group	Neutral
Solaris Resources	Neutral

Cronos Group presently has a consensus price target of C$4.75, suggesting a potential upside of 19.65%. Solaris Resources has a consensus price target of C$19.50, suggesting a potential upside of 80.72%. Given Solaris Resources' higher possible upside, analysts plainly believe Solaris Resources is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Solaris Resources	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Solaris Resources beats Cronos Group on 6 of the 11 factors compared between the two stocks.

Get Cronos Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRON vs. The Competition

Export

Metric	Cronos Group	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$1.45B	C$2.25B	C$6.88B	C$12.48B
Dividend Yield	N/A	2.81%	2.67%	6.19%
P/E Ratio	-188.00	5.00	27.00	36.95
Price / Sales	9.30	1,642.24	491.80	9.44
Price / Cash	1.67	10.18	50.54	82.29
Price / Book	1.34	9.91	10.28	4.39
Net Income	-C$32.78M	C$20.27B	C$3.60B	C$299.09M
7 Day Performance	1.28%	-0.87%	-1.25%	0.61%
1 Month Performance	2.32%	0.08%	-0.35%	1.06%
1 Year Performance	41.79%	7.16%	18.41%	30.89%

Cronos Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRON Cronos Group	1.9672 of 5 stars	C$3.97 +2.3%	C$4.75 +19.6%	+40.8%	C$1.45B	C$159.54M	N/A	450
APHA Aphria	N/A	N/A	N/A	N/A	C$5.24B	C$611.06M	N/A	1,200
PBH Premium Brands	3.6785 of 5 stars	C$90.86 +0.6%	C$118.62 +30.5%	0.0%	C$4.72B	C$7.88B	100.96	540
BHC Bausch Health Companies	0.895 of 5 stars	C$6.94 +1.3%	N/A	-32.4%	C$2.59B	C$10.53B	N/A	19,900	News Coverage Analyst Upgrade Analyst Revision
AUP Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	C$2.15B	C$57.59M	N/A	300	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CRON) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cronos Group (CRON) Competitors

CRON vs. APHA, PBH, BHC, AUP, and SLS

How does Cronos Group compare to Aphria?

Summary

How does Cronos Group compare to Premium Brands?

Summary

How does Cronos Group compare to Bausch Health Companies?

Summary

How does Cronos Group compare to Aurinia Pharmaceuticals?

Summary

How does Cronos Group compare to Solaris Resources?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRON vs. The Competition

Cronos Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cronos Group (CRON) Competitors

CRON vs. APHA, PBH, BHC, AUP, and SLS

How does Cronos Group compare to Aphria?

Do analysts prefer APHA or CRON?

Do insiders & institutionals have more ownership in APHA or CRON?

Which has higher valuation & earnings, APHA or CRON?

Does the media prefer APHA or CRON?

Is APHA or CRON more profitable?

Summary

How does Cronos Group compare to Premium Brands?

Which has preferable earnings and valuation, PBH or CRON?

Do insiders and institutionals have more ownership in PBH or CRON?

Does the media favor PBH or CRON?

Do analysts prefer PBH or CRON?

Is PBH or CRON more profitable?

Which has more volatility and risk, PBH or CRON?

Summary

How does Cronos Group compare to Bausch Health Companies?

Do insiders & institutionals have more ownership in CRON or BHC?

Does the media prefer CRON or BHC?

Do analysts rate CRON or BHC?

Is CRON or BHC more profitable?

Which has more risk & volatility, CRON or BHC?

Which has higher earnings and valuation, CRON or BHC?

Summary

How does Cronos Group compare to Aurinia Pharmaceuticals?

Do analysts rate CRON or AUP?

Does the media refer more to CRON or AUP?

Do insiders and institutionals hold more shares of CRON or AUP?

Is CRON or AUP more profitable?

Which has stronger earnings and valuation, CRON or AUP?

Summary

How does Cronos Group compare to Solaris Resources?

Is CRON or SLS more profitable?

Which has better earnings & valuation, CRON or SLS?

Do institutionals and insiders hold more shares of CRON or SLS?

Which has more risk and volatility, CRON or SLS?

Does the media prefer CRON or SLS?

Do analysts rate CRON or SLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRON vs. The Competition

Cronos Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools